INYX ANNOUNCES STRATEGIC U.K. ACQUISITION OF CELLTECH MANUFACTURING SERVICES LIMITED FROM UCB

Inyx, Inc. (OTC Bulletin Board: IYXI), a specialty pharmaceutical company with a focus on niche drug delivery technologies and products, announced today that it and UCB, a global biopharmaceutical company headquartered in Brussels, Belgium, have signed a definitive agreement whereby Inyx will acquire from UCB all the outstanding shares of Celltech Manufacturing Services Limited (CMSL), a UCB subsidiary based in Ashton, England. The purchase price is 27.5 million Euros and will be financed through a non-dilutive, asset-based funding facility provided by Westernbank Business Credit Division of Westernbank Puerto Rico. The acquisition is set to close on August 31, 2005.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/08-26-2005/0004094729&EDATE=)